Journal
JOURNAL OF MOLECULAR LIQUIDS
Volume 297, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.molliq.2019.111898
Keywords
Covalent triazine-based framework; CTF; Sorafenib; Drug delivery; Drug controlled release
Funding
- Research Affairs Division Isfahan University of Technology (IUT), Isfahan
Ask authors/readers for more resources
In the present study, a novel polyimine-based covalent triazine framework (PI-CTF) was introduced as a promising biocompatible carrier for sorafenib (SFN) delivery. High specific surface area and porosity allowed us to achieve drug loading and encapsulation efficiency as high as 83% and 98%, respectively. The in vitro drug release study of SFN-loaded PI-CTF showed a sustained and pH-dependent release behavior in which acidic pH accelerated drug release compared with the neutral pH. Notably, cytotoxicity assay against L929 cells revealed the safety and biocompatibility of PI-CTF. Moreover, MTT assay against LNCaP prostate cancer cells expressed that the anticancer activity of SFN had no diminution after incorporating into PI-CTF. Thus, PI-CTF has envisaged as a great promise toward anti-cancer drug carrier. (C) 2019 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available